SCHEMBL4409246

SCHEMBL4409246

CCOC(=O)/C(=C\N(C)C)C(=O)c1cc(Br)c(OC)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.39
MAPT P10636 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 2/20 0.39
PLIN1 O60240 1/20 0.39
PLIN5 Q00G26 1/20 0.39
ABHD5 Q8WTS1 1/20 0.39
NPSR1 Q6W5P4 3/20 0.38
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 2/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 6/20 0.37
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409249 1.00 LMNA (0.39) LMNAMAPTMEN1KMT2APOLB
SCHEMBL1300338 0.89 LMNA (0.41) LMNAMAPTMEN1KMT2APOLB
SCHEMBL1300340 0.89 LMNA (0.41) LMNAMAPTMEN1KMT2APOLB
SCHEMBL13225679 0.88 MEN1 (0.39) LMNAMAPTMEN1KMT2ANPSR1
SCHEMBL12931114 0.86 MAPT (0.39) LMNAMAPTMEN1KMT2APOLB
SCHEMBL9720539 0.85 MEN1 (0.39) LMNAMAPTMEN1KMT2ANPSR1
SCHEMBL9720544 0.85 MEN1 (0.39) LMNAMAPTMEN1KMT2ANPSR1
SCHEMBL13008086 0.85 CYP11B1 (0.37) LMNAMAPTMEN1KMT2ANPSR1
SCHEMBL6339979 0.82 KMT2A (0.42) LMNAMAPTMEN1KMT2ANPSR1
SCHEMBL17193050 0.82 KMT2A (0.42) LMNAMAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130345462-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2013-12-26 US disclosed
US-8420821-B2 Process for production of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-04-16 US disclosed
US-8420821-B2 Process for production of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-04-16 US disclosed
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-12-24 US disclosed
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345462-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 LMNA 2635/4885MAPT 4765/4885MEN1 3040/4885
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 LMNA 2635/4885MAPT 4765/4885MEN1 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.